Yoshimi A, Hashizume H, Kitagawa M, Nishimura K, Kakeya N
Research Laboratories, Kyoto Pharmaceutical Industries, Ltd., Japan.
Biol Pharm Bull. 1993 Apr;16(4):375-8. doi: 10.1248/bpb.16.375.
To clarify the absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy+ ++)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate (DSCG), a study was made using rats. N-556 gave the highest plasma level of DSCG following its injection into the loop at the upper part of the small intestine. N-556 was stable in acidic washings of gastric contents, but rapidly hydrolyzed to M1 with twin ethyl residues on DSCG in the washings of the small intestinal contents. N-556 and M1 were hydrolyzed to DSCG via M2 having a mono ethyl residue in the homogenate of the small intestinal mucosa. The oral absorption of M1 following its administration in 50% (v/v) propylene glycol solution was essentially the same as that of N-556. That of M1 administered in aqueous suspension was low. After the oral administration of N-556, a small amount of M2 and a trace of M3 having L-lysyl residue were detected in the portal plasma, but no hydrolytic intermediate except DSCG could be found in the general plasma. The major absorption mechanism of N-556 may thus be concluded as follows: N-556 given orally is transferred to the small intestine in essentially intact form. N-556 is then rapidly diffused to an aqueous layer on the surface of the mucosal membrane and hydrolyzed to M1. The resultant M1 is transported to the mucosal membrane and hydrolyzed to DSCG via M2. DSCG generated in the mucosal membrane is used for general circulation through the portal blood and liver.(ABSTRACT TRUNCATED AT 250 WORDS)
为阐明色甘酸钠(DSCG)口服前体药物1,3 - 双(2 - 乙氧羰基色原酮 - 5 - 氧基)- 2 - [(S)- 赖氨酰氧基]丙烷二盐酸盐(N - 556)的吸收机制,用大鼠进行了一项研究。将N - 556注入小肠上部肠袢后,其产生的DSCG血浆水平最高。N - 556在胃内容物的酸性洗液中稳定,但在小肠内容物的洗液中迅速水解为带有双乙基残基的M1。在小肠黏膜匀浆中,N - 556和M1通过带有单乙基残基的M2水解为DSCG。M1以50%(v/v)丙二醇溶液给药后的口服吸收与N - 556基本相同。M1以水混悬液给药时吸收较低。口服N - 556后,在门静脉血浆中检测到少量M2和痕量带有L - 赖氨酰残基的M3,但在一般血浆中未发现除DSCG外的水解中间体。因此,N - 556的主要吸收机制可总结如下:口服给予的N - 556以基本完整的形式转移至小肠。然后N - 556迅速扩散至黏膜表面的水层并水解为M1。生成的M1转运至黏膜并通过M2水解为DSCG。在黏膜中产生的DSCG通过门静脉血和肝脏进行体循环。(摘要截短至250字)